Incidence and risk factors for progressive multifocal leukoencephalopathy among patients with selected rheumatic diseases

Arthritis Care and Research

Volumn 64, Issue 4, 2012, Pages 612-615

  Bharat, A ^a   Xie, F ^a   Baddley, J W ^a   Beukelman, T ^a   Chen, L ^a   Calabrese, L ^b   Delzell, E ^a   Grijalva, C G ^c   Patkar, N M ^a   Saag, K ^a   Winthrop, K L ^d   Curtis, J R ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

^c VANDERBILT UNIVERSITY   (United States)

^d OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL FACTOR; RITUXIMAB;

ANKYLOSING SPONDYLITIS; ARTICLE; AUTOIMMUNE DISEASE; ENTERITIS; HOSPITAL PATIENT; HOSPITALIZATION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; JUVENILE RHEUMATOID ARTHRITIS; NEOPLASM; OUTPATIENT; POPULATION RESEARCH; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PSORIASIS; PSORIATIC ARTHRITIS; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; RISK FACTOR;

AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; HUMANS; INCIDENCE; LEUKOENCEPHALOPATHY, PROGRESSIVE MULTIFOCAL; RETROSPECTIVE STUDIES; RHEUMATIC DISEASES; RISK FACTORS; TUMOR NECROSIS FACTOR-ALPHA; UNITED STATES;

EID: 84859741498     PISSN: 00043591     EISSN: 21514658     Source Type: Journal    
DOI: 10.1002/acr.21564     Document Type: Article

References (19)

1. Boothpur R, Brennan DC. Human polyoma viruses and disease with emphasis on clinical BK and JC. J Clin Virol 2010; 47:306-12.
2. Brew BJ, Davies NW, Cinque P, Clifford DB, Nath A. Progressive multifocal leukoencephalopathy and other forms of JC virus disease. Nat Rev Neurol 2010;6:667-79.
3. Marzocchetti A, Wuthrich C, Tan CS, Tompkins T, Bernal-Cano F, Bhargava P, et al. Rearrangement of the JC virus regulatory region sequence in the bone marrow of a patient with rheumatoid arthritis and progressive multifocal leukoencephalopathy. J Neurovirol 2008;14:455-8. (Pubitemid 352762885)
4. Rankin E, Scaravilli F. Progressive multifocal leukoencephalopathy in a patient with rheumatoid arthritis and polymyositis. J Rheumatol 1995;22:777-9.
5. Molloy ES, Calabrese LH. Progressive multifocal leukoencephalopathy in patients with rheumatic diseases: are patients with systemic lupus erythematosus at particular risk? Autoimmun Rev 2008;8:144-6.
6. Molloy ES, Calabrese LH. Progressive multifocal leukoencephalopathy: a national estimate of frequency in systemic lupus erythematosus and other rheumatic diseases. Arthritis Rheum 2009;60:3761-5.
7. Boren EJ, Cheema GS, Naguwa SM, Ansari AA, Gershwin ME. The emergence of progressive multifocal leukoencephalopathy (PML) in rheumatic diseases. J Autoimmun 2008;30:90-8.
8. Calabrese LH, Molloy ES. Progressive multifocal leucoencephalopathy in the rheumatic diseases: assessing the risks of biological immunosuppressive therapies. Ann Rheum Dis 2008;67 Suppl:iii64-5.
9. Calabrese LH, Molloy ES, Huang D, Ransohoff RM. Progressive multifocal leukoencephalopathy in rheumatic diseases: evolving clinical and pathologic patterns of disease [review]. Arthritis Rheum 2007;56:2116-28. (Pubitemid 47173558)
10. Clifford DB, Ances B, Costello C, Rosen-Schmidt S, Andersson M, Parks D, et al. Rituximab-associated progressive multifocal leukoencephalopathy in rheumatoid arthritis. Arch Neurol 2011;68:1156-64.
11. Ota I, Katsura Y, Yoshida C, Yoshizawa K, Ohtani H, Sata T, et al. Progressive multifocal leukoencephalopathy after rituximab therapy in a patient with mantle cell lymphoma. Rinsho Ketsueki 2010;51:1786-8. In Japanese.
12. Paues J, Vrethem M. Fatal progressive multifocal leukoencephalopathy in a patient with non-Hodgkin lymphoma treated with rituximab. J Clin Virol 2010;48:291-3.
13. Tuccori M, Focosi D, Blandizzi C, Pelosini M, Montagnani S, Maggi F, et al. Inclusion of rituximab in treatment protocols for non-Hodgkin's lymphomas and risk for progressive multifocal leukoencephalopathy. Oncologist 2010;15:1214-9.
14. Khalili K, White MK, Lublin F, Ferrante P, Berger JR. Reactivation of JC virus and development of PML in patients with multiple sclerosis. Neurology 2007;68:985-90. (Pubitemid 46569130)
15. Korman BD, Tyler KL, Korman NJ. Progressive multifocal leukoencephalopathy, efalizumab, and immunosuppression: a cautionary tale for dermatologists. Arch Dermatol 2009;145: 937-42.
16. Kumar D, Bouldin TW, Berger RG. A case of progressive multifocal leukoencephalopathy in a patient treated with infliximab. Arthritis Rheum 2010;62:3191-5.
17. Lavagna A, Bergallo M, Daperno M, Sostegni R, Costa C, Leto R, et al. Infliximab and the risk of latent viruses reactivation in active Crohn's disease. Inflamm Bowel Dis 2007;13:896-902. (Pubitemid 47203868)
18. Fleischmann RM. Progressive multifocal leukoencephalopathy following rituximab treatment in a patient with rheumatoid arthritis. Arthritis Rheum 2009;60:3225-8.
19. Molloy ES, Calabrese LH. Progressive multifocal leukoencephalopathy associated with biologic and synthetic DMARD therapy in rheumatic diseases: an analysis of the FDA Adverse Event Reporting System database [abstract]. Arthritis Rheum 2010;62 Suppl:S292.